Novo Nordisk A/S

NVO is in a Stage 4 decline with all EMAs sloping downward and price trading below key moving averages. The medium-term bias is bearish, reinforced by the Bearish Pivot Point pattern and resistance at the 50- and 200-day SMAs. Short-term momentum favors continued downside, so selling now into any rally toward the EMA/SMA cluster is advised.

• ↑Q1 2026 sales rose 32% to DKK 96.8 bn, with 62% GLP-1 market share.
• ↑High profitability and strong earnings yield support attractive valuation.
• ↓Lost 9% global GLP-1 share; Bernstein cut 2026 EPS forecasts 7% below consensus.